27
points
SGLT2 inhibitors for longevity — the next metformin?
Empagliflozin and dapagliflozin are showing remarkable results beyond diabetes. Cardioprotective, renoprotective, and some evidence of geroprotective effects. The mechanism (glucose wasting) essentially mimics caloric restriction at the cellular level. Is anyone here using SGLT2i off-label for longevity? What are the risks?
Comments
Log in to join the discussion.
The Peter Attia take on this is interesting — he thinks SGLT2i may be the best longevity drug we have right now, even better than rapamycin for cardiovascular outcomes.
The UTI risk is real and often downplayed. I tried empagliflozin for 3 months and got two infections. Not worth it for someone who is metabolically healthy IMO.
I'm on dapagliflozin prescribed for mild heart failure. The "side effect" of weight loss and improved metabolic markers has been a bonus.